PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage

Zhang,Yun‑Fang; Wang,Qi; Su,Yan‑Yan; Wang,Jie‑Lin; Hua,Bao‑Jun; Yang,Shen; Feng,Jun‑Xia; Li,Hong‑Yan

doi:10.3892/mmr.2017.6196

PPAR‑γ agonist rosiglitazone protects rat peritoneal mesothelial cells against peritoneal dialysis solution‑induced damage

Authors:
- Yun‑Fang Zhang
- Qi Wang
- Yan‑Yan Su
- Jie‑Lin Wang
- Bao‑Jun Hua
- Shen Yang
- Jun‑Xia Feng
- Hong‑Yan Li
View Affiliations

Affiliations: Center of Kidney Disease, Huadu District People's Hospital, Southern Medical University, Guangzhou, Guangdong 510800, P.R. China
Published online on: February 13, 2017 https://doi.org/10.3892/mmr.2017.6196
Pages: 1786-1792

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long-term peritoneal dialysis (PD) leads to ultrafiltration failure (UFF). Peritoneal mesothelial cells, which form the innermost monolayer of the peritoneal cavity, have been shown to regulate various responses, including inflammation, in UFF. The present study was designed to investigate the effect of the peroxisome proliferator‑activated receptor‑γ (PPAR‑γ) agonist, rosiglitazone, on peritoneal dialysis solution (PDS)‑induced injuries in rat peritoneal mesothelial cells (RPMCs). RPMCs were cultured for different durations and with different concentrations of PDS. The gene expression levels of aquaporin‑1 (AQP‑1) and zonula occluden‑1 (ZO‑1) were determined using reverse transcription‑quantitative polymerase chain reaction analysis. The protein levels of AQP‑1, ZO‑1 and PPAR‑γ were measured using western blot analysis. Interleukin (IL)‑6 and IL‑8 were detected using ELISA. The RPMCs were damaged by stimulation with 4.25% PDS for 72 h. The expression levels of AQP‑1 and ZO‑1 were increased, and the secretion of IL‑6 and IL‑8 were decreased by rosiglitazone. The use of the PPAR‑γ inhibitor, GW‑9662, completely prevented the effects of rosiglitazone. These results indicated that PDS exposure stimulated an inflammatory response in the RPMCs. The PPAR‑γ activator, rosiglitazone, appeared to relieve the injury by inhibiting inflammation, and regulating the expression of AQP‑1 and ZO‑1, however further investigations are required to elucidate the potential underlying mechanism.

View Figures

View References

1	Ditsawanon P and Aramwit P: Preserving the peritoneal membrane in long-term peritoneal dialysis patients. J Clin Pharm Ther. Aug 17–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
2	Yuvaraj A, Koshy PJ, Rohit A, Nagarajan P, Nair S, Revathi L and Abraham G: Diagnostic dilemma of ultrafiltration failure in a continuous ambulatory peritoneal dialysis patient. Perit Dial Int. 35:233–234. 2015. View Article : Google Scholar : PubMed/NCBI
3	Teitelbaum I: Ultrafiltration failure in peritoneal dialysis: A pathophysiologic approach. Blood Purif. 39:70–73. 2015. View Article : Google Scholar : PubMed/NCBI
4	Fusshoeller A: Histomorphological and functional changes of the peritoneal membrane during long-term peritoneal dialysis. Pediatr Nephrol. 23:19–25. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ranzinger J, Rustom A and Schwenger V: Membrane nanotubes between peritoneal mesothelial cells: Functional connectivity and crucial participation during inflammatory reactions. Front Physiol. 5:4122014. View Article : Google Scholar : PubMed/NCBI
6	Morelle J and Devuyst O: Water and solute transport across the peritoneal membrane. Curr Opin Nephrol Hypertens. 24:434–443. 2015. View Article : Google Scholar : PubMed/NCBI
7	Kaneda K, Miyamoto K, Nomura S and Horiuchi T: Intercellular localization of occludins and ZO-1 as a solute transport barrier of the mesothelial monolayer. J Artif Organs. 9:241–250. 2006. View Article : Google Scholar : PubMed/NCBI
8	Devuyst O and Rippe B: Water transport across the peritoneal membrane. Kidney Int. 85:750–758. 2014. View Article : Google Scholar : PubMed/NCBI
9	Han JY, Kim YJ, Kim L, Choi SJ, Park IS, Kim JM, Chu YC and Cha DR: PPARgamma agonist and angiotensin II receptor antagonist ameliorate renal tubulointerstitial fibrosis. J Korean Med Sci. 25:35–41. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ma L, Shao Z, Wang R, Zhao Z, Dong W and Zhang J, Zhang X, Sheng S, Ji Z and Zhang J: Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway. Am J Med Sci. 350:121–128. 2015. View Article : Google Scholar : PubMed/NCBI
11	Zhang YF, Zou XL, Wu J, Yu XQ and Yang X: Rosiglitazone, a peroxisome proliferator-activated receptor (PPAR)-γ agonist, attenuates inflammation via NF-kB inhibition in lipopolysaccharide-induced peritonitis. Inflammation. 38:2105–2115. 2015. View Article : Google Scholar : PubMed/NCBI
12	Aramwit P, Bunmee P and Supasyndh O: Effectiveness and tolerability of rosiglitazone on insulin resistance and body composition in nondiabetic Thai patients undergoing continuous ambulatory peritoneal dialysis: A 12-week pilot study. Curr Ther Res Clin Exp. 70:377–389. 2009. View Article : Google Scholar : PubMed/NCBI
13	Nie J, Dou X, Hao W, Wang X, Peng W, Jia Z, Chen W, Li X, Luo N, Lan HY and Yu XQ: Smad7 gene transfer inhibits peritoneal fibrosis. Kidney Int. 72:1336–1344. 2007. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Guo J, Xiao J, Gao H, Jin Y and Zhao Z, Jiao W, Liu Z and Zhao Z: Cyclooxygenase-2 and vascular endothelial growth factor expressions are involved in ultrafiltration failure. J Surg Res. 188:527–536.e2. 2014. View Article : Google Scholar : PubMed/NCBI
16	Devuyst O and Yool AJ: Aquaporin-1: New developments and perspectives for peritoneal dialysis. Perit Dial Int. 30:135–141. 2010. View Article : Google Scholar : PubMed/NCBI
17	Ni J, Verbavatz JM, Rippe A, Boisdé I, Moulin P, Rippe B, Verkman AS and Devuyst O: Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int. 69:1518–1525. 2006. View Article : Google Scholar : PubMed/NCBI
18	Qiu L, Chen C, Ding G, Zhou Y and Zhang M: The effects of electromagnetic pulse on the protein levels of tight junction associated-proteins in the cerebral cortex, hippocampus, heart, lung, and testis of rats. Biomed Environ Sci. 24:438–444. 2011.PubMed/NCBI
19	Hawkins BT and Davis TP: The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 57:173–185. 2005. View Article : Google Scholar : PubMed/NCBI
20	Ito T, Yorioka N, Kyuden Y, Asakimori Y, Kiribayashi K, Ogawa T and Kohno N: Effect of glucose polymer on the intercellular junctions of cultured human peritoneal mesothelial cells. Nephron Clin Pract. 93:c97–c105. 2003. View Article : Google Scholar : PubMed/NCBI
21	Leung JC, Chan LY, Li FF, Tang SC, Chan KW, Chan TM, Lam MF, Wieslander A and Lai KN: Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: The role of VEGF. Nephrol Dial Transplant. 20:1336–1349. 2005. View Article : Google Scholar : PubMed/NCBI
22	Leitch V, Agre P and King LS: Altered ubiquitination and stability of aquaporin-1 in hypertonic stress. Proc Natl Acad Sci USA. 98:2894–2898. 2001. View Article : Google Scholar : PubMed/NCBI
23	Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takazoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, et al: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 51:182–186. 1997. View Article : Google Scholar : PubMed/NCBI
24	van Hooland S, Boey O, Van der Niepen P, Van den Branden C and Verbeelen D: Effect of short-term rosiglitazone therapy in peritoneal dialysis patients. Perit Dial Int. 29:108–111. 2009.PubMed/NCBI
25	Sandoval P, Loureiro J, González-Mateo G, Pérez-Lozano ML, Maldonado-Rodríguez A, Sánchez-Tomero JA, Mendoza L, Santamaría B, Ortiz A, Ruíz-Ortega M, et al: PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Lab Invest. 90:1517–1532. 2010. View Article : Google Scholar : PubMed/NCBI
26	Sauter M, Kastenmüller K, Belling F, Wörnle M, Ladurner R, Mussack T and Sitter T: Activation of peroxisome proliferator-activated receptor-gamma by glitazones reduces the expression and release of monocyte chemoattractant protein-1 in human mesothelial cells. Mediators Inflamm. 2012:2176962012. View Article : Google Scholar : PubMed/NCBI
27	Yao Q, Ayala ER, Qian JQ, Stenvinkel P, Axelsson J and Lindholm B: A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. Clin Nephrol. 68:295–301. 2007.PubMed/NCBI